{
  "id": 17312560,
  "title": "Cathie Wood’s ARK sells Eli Lilly stock, buys Tempus AI and Coinbase",
  "url": "https://urgent.news/2026/10/31/cathie-woods-ark-sells-eli-lilly-stock-buys-tempus-ai-and-coinbase",
  "topic": "ai",
  "section": "AI",
  "published": "2026-10-31T00:04:33.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/cathie-woods-ark-sells-eli-lilly-stock-buys-tempus-ai-and-coinbase-93CH-4988958"
  },
  "original_language": "en",
  "account": "Cathie Wood's ARK ETF detailed their trades for Friday, October 30th, 2026, revealing a mix of strategic sales and acquisitions. The largest transaction was the sale of 17,626 shares of Eli Lilly and Company (NYSE:LLY) through the ARKK ETF, totaling $24,212,836. This aligns with ARK's recent pattern of reducing exposure to Eli Lilly after prior sales in the biotech space. On the purchase front, ARK invested $12,027,914 in Tempus AI (NASDAQ:TEM), buying 154,521 shares across the ARKK and ARKG ETFs. This follows ARK's prior sales of Tempus AI shares earlier in the week. Another significant addition was 39,418 shares of Coinbase Global (NASDAQ:COIN) across the ARKK, ARKW, and ARKF ETFs, valued at $6,330,136, showcasing ARK's ongoing trust in the cryptocurrency exchange platform. ARK also increased holdings in Circle Internet Group (NASDAQ:CRCL) by purchasing 74,894 shares for $5,990,771, following a previous sell-off, indicating a strategic repositioning. In healthcare, ARK invested in Pacific Biosciences of California (NASDAQ:PACB) by buying 480,274 shares for $1,392,794, supporting their focus on genomics and biotech innovations. ARK expanded its stake in Robinhood Markets (NASDAQ:HOOD) with 13,757 shares through the ARKF ETF, valued at $1,260,003, after a notable purchase earlier in the week. The ETF sold 238,373 shares of Bullish (NYSE:BLSH) across the ARKK, ARKW, and ARKF, totaling $6,786,479, signaling a strategic exit from the digital asset trading platform. Lastly, ARK decreased its position in CareDx (NASDAQ:CDNA) by selling 50,859 shares thru the ARKG ETF for $3,637,435, continuing its trend of trimming biotech firm holdings. These trades highlight ARK's dynamic strategy, balancing high-growth investments with selective divestments.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}